<DOC>
	<DOCNO>NCT02993406</DOCNO>
	<brief_summary>The purpose study determine treatment bempedoic acid ( ETC-1002 ) versus placebo decrease risk cardiovascular event patient statin intolerant .</brief_summary>
	<brief_title>Evaluation Major Cardiovascular Events Patients With , High Risk , Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid ( ETC-1002 ) Placebo</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Patient report history statin intolerance ( inability tolerate 2 statin , one low dose ) Men nonpregnant , nonlactating woman Fasting blood LDLcholesterol 100 190 mg/dL screen History , high risk , cardiovascular disease ( CVD ) include coronary artery disease , symptomatic peripheral arterial disease , cerebrovascular atherosclerotic disease , high risk cardiovascular event Fasting blood triglyceride great 500 mg/dL screen Recent history certain cardiovascular disease include transient ischemic attack ( TIA ) , unstable symptomatic cardiac arrhythmia , use implantable pacemaker implantable cardioverter defibrillator , coronary revascularization procedure History heart failure Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>